Bioniche Pharma introduces Octreotide Acetate Injection USP

Bioniche Pharma claims Octreotide Acetate Injection USP is the generic version of Novartis’ Sandostatin, indicated for the treatment of acromegaly.

The injection was developed by Chemi and is being manufactured by Italfarmaco.

Mylan Institutional president Matt Erick said the approval is particularly important because it is the first and only PFS for this product -brand or generic- providing hospitals and clinics access to a preferred presentation that offers ease, accuracy and convenience of dosing.

"The addition of Octreotide Acetate Injection as Mylan Institutional’s first PFS is a critical next step in expanding their already portfolio of injectable products," Erick said.